A rule of the Food and Drug Administration (FDA) which gives protection against disclosure to reports of serious adverse effects of drugs and product problems which have been voluntarily reported to pharmaceutical, biological, and medical device manufacturers. This rule, which preempts state discovery laws, became effective in July 1995.